ORIC Pharmaceuticals Raises $264M, Advances Key Oncology Candidates

Event summary

  • ORIC raised $264M in 2025, extending runway into 2H 2028.
  • Rinzimetostat showed potential best-in-class efficacy in mCRPC with 55% PSA50 response.
  • Enozertinib demonstrated 100% intracranial ORR in NSCLC with EGFR mutations.
  • Phase 3 monotherapy dose for enozertinib selected; registrational trials anticipated.

The big picture

ORIC's strategic focus on overcoming therapeutic resistance in oncology aligns with the industry's shift toward precision medicine. The $264M raise positions the company to compete with larger players in prostate and lung cancer markets, where targeted therapies are increasingly replacing broad-spectrum treatments. The collaboration with Johnson & Johnson further validates enozertinib's potential in EGFR-mutated NSCLC.

What we're watching

Clinical Execution
Whether ORIC can sustain the momentum of its Phase 1b data in larger registrational trials.
Competitive Positioning
How rinzimetostat and enozertinib differentiate against existing and emerging therapies.
Financial Discipline
The pace at which ORIC burns through its $412M cash position as it advances multiple programs.